Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated October 16, 2024, reports the appointment of a new Chief Financial Officer (CFO) for Pacira Biosciences, Inc. The appointment is effective October 21, 2024. The filing does not contain financial results for a specific reporting period but focuses on executive compensation and corporate governance changes.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the compensation package for the newly appointed CFO, Shawn M. Cross:
- Base Salary: $525,000 annually.
- Annual Incentive Target: 50% of base salary.
- Equity Grants: 200,000 nonqualified stock options and 75,000 restricted stock units (RSUs).
- Severance (Non-Change of Control): 12 months of salary continuation and 9 months of accelerated equity vesting.
- Severance (Change of Control): 18 months of salary continuation, 150% of target bonus, and full acceleration of equity vesting.
Material Changes
The primary material change is the leadership transition in the finance function. Shawn M. Cross succeeds Lauren Riker, who served as interim CFO starting October 1, 2024. Ms. Riker will remain as Senior Vice President of Finance and principal accounting officer. Mr. Cross brings over 20 years of investment banking experience in the biopharmaceutical sector, including recent roles as CEO and CFO at Applied Molecular Transport, Inc.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of market risks. The primary contingency noted is the requirement for Mr. Cross to execute a severance and general release of claims to receive any termination benefits. The full Employment Agreement will be filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2024.
Investor Verification Checklist
- Verify the exact exercise price of the 200,000 stock options, which is set based on the closing stock price on November 4, 2024.
- Review the full text of the Employment Agreement once filed in the 2024 Form 10-K to confirm definitions of "cause" and "good reason."
- Monitor the transition period to ensure continuity in SEC reporting under the new CFO leadership.
- Confirm the vesting schedule details for the 75,000 RSUs, which begin vesting on November 1, 2025.